This discrepancy was documented in Rejeb et al [22] who showed widely variable rate of p53 expression ranging from 1.1% in localised tumours to 54.7% in surgically treated PCa which may be attributed to differences in the methodology of p53 immunostaining assessment, the differences in the techniques, studied specimens (one section or multiple cores of tumour tissue) and patient’s stage (primary tumours, metastasis). The gene discussed is TP53; the disease is neoplasm.